Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
A 4 week-duration cross-over study on Ticagrelor and Clopidogrel for the Acute Coronary
Syndrome (ACS) and Chronic Kidney Disease (CKD) subjects, focusing on the platelet inhibition
and safety observation.